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Abstract
Understanding the importance of the gut microbiome on modulation of host health has become a 
subject of great interest for researchers across disciplines. As an intrinsically multidisciplinary 
field, microbiome research has been able to reap the benefits of technological advancements in 
systems and synthetic biology, biomaterials engineering, and traditional microbiology. Gut 
microbiome research has been revolutionized by high-throughput sequencing technology, 
permitting compositional and functional analyses that were previously an unrealistic undertaking. 
Emerging technologies including engineered organoids derived from human stem cells, high-
throughput culturing, and microfluidics assays allowing for the introduction of novel approaches 
will improve the efficiency and quality of microbiome research. Here, we will discuss emerging 
technologies and their potential impact on gut microbiome studies.
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The Gut Microbiome
Humans are associated in a symbiotic relationship with up to 1014 microorganisms [1]. The 
majority of these host-associated microbes reside within the gastrointestinal tract, and have 
extraordinary metabolic potential, playing a pivotal role in human health [2]. The gut 
microbiota enhances the host's response to pathogen invasion [3], modulates host gene 
expression and immune response, and ultimately impacts overall health [4-6]. Normal 
inhabitants of the gastrointestinal tract facilitate the metabolism of polysaccharides 
consumed by the host [7] and interactions between microbes within the microbiota enhance 
this metabolic potential, further improving polysaccharide utilization [8]. Other health-
supporting functions of gut microorganisms include disease protection through 
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immunomodulation [9] as has been shown for Bifidobacterium longum, which strongly 
stimulates production of interleukin-10 and proinflammatory cytokines including TNF-α [9] 
that protects the host against tumor proliferation [10]. Furthermore, Bifidobacterium and 
other lactic acid bacteria often produce exopolysaccharides (EPS), complex polymers that 
can be used as fermentable substrates by other gut microbes aiding in microbial community 
structure and stability [11].
Compositional perturbations of the microbiota (dysbioses) (See Glossary) have been 
associated with diseases including obesity [12], diabetes [13], colorectal cancer [14], and 
allergies [15]. Hence maintaining compositional and functional stability within gut 
microbiome is essential to host health as demonstrated by dysbioses detected at the onset of 
nonpathogenic chronic diseases [4, 5] like Crohn's disease, where the gut microbiome had a 
significant decrease in beneficial Bifidobacteriaceae populations while exhibiting an 
increase in groups containing potential pathogens including Enterobacteriaceae, 
Pasteurellaceae, Fusobacteriaceae, and Neisseriaceae [16].
Current high-throughput sequencing technologies provide important information about the 
composition and functionality of the gut microbiome. However, in order to better understand 
mechanistic interactions between the gut microbiota and its host, and the importance of the 
gut microbiome in maintaining health, it is critical to explore new research approaches and 
integrate emerging technologies from multiple branches of biology and engineering [17]. 
The present review will discuss recent breakthroughs in microbiome studies and 
biotechnological advancements that may improve our ability to study the gut microbiome in 
the future.
The Study of the Gut Microbiome Before Next-Generation Sequencing 
(NGS)
Prior to the advent of NGS, the accurate identification of most members of a complex 
microbial community was challenging. This was especially true for the gut microbiome, a 
highly diverse community and one of the densest microbial communities on the planet, with 
a small percentage of culturable microbes [18]. Early gut microbiome studies involved 
cultivation of individual bacteria [19], and studies of interactions by co-culture of microbial 
consortia [20]. While these methods allowed investigation of basic microbial interactions, 
they provided little information about community dynamics, as uncultivable microbes were 
excluded from analysis and organisms were outside of their natural environment. Cultivation 
based approaches to study microbial communities are still important today; however, new 
techniques have emerged over time enabling the study of communities in greater detail 
without omitting uncultivable microbes. Early methods to determine microbiome 
composition allowed the differences between microbial communities to be discerned, but 
offered little information regarding taxonomic composition of communities. Terminal-
restriction fragment length polymorphism (T-RFLP) for example was used to identify gut 
dysbioses associated with necrotizing enterocolitis (NEC) in animal models, suggesting a 
significant role for Clostridium in pathogenesis [21]. Similarly, a denaturing gradient gel 
electrophoresis (DGGE) study showed that the human gut microbiome was disrupted by 
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antibiotic administration but the impact was variable between patients, consistent with data 
obtained by culture-dependent methods [22]. Finally, temperature gradient gel 
electrophoresis (TGGE) showed a direct correlation between Sphingomonas with NEC in 
human infants, and associated antimicrobial treatments with significantly reduced gut 
microbial diversity [23].
As DNA sequencing technology emerged, the ability to study the composition of complex 
microbial communities improved, allowing for more precise and rapid taxonomic 
identification of individuals within those communities. Early sequencing technologies were 
slow and expensive. Sequencing analysis of the 16S rRNA gene was originally performed 
by cloning the full gene into plasmid vectors, transforming it into suitable hosts (usually 
Escherichia coli), and sequencing it [24]. Due to the cost of sequencing at the time, other 
methods like Southern blotting and in situ hybridization made use of the 16S rRNA clone 
libraries to identify members of complex microbial communities [25].
More recent PCR-based massive parallel sequencing technologies have drastically increased 
throughput of microbiome analyses [26]. With the ability to enrich templates with initial 
concentrations too low to detect, PCR based sequencing technology allows identification of 
individuals with very low populations within complex communities. PCR-based sequencing 
strategies along with advancements in the availability of bioinformatics tools opened the 
door to modern day NGS technology.
While advanced bioinformatics platforms for data analysis provide an invaluable tool for 
microbiome research (Box 1), vast amounts of data obtained through high throughput 
sequencing far surpasses the ability to analyze that data, creating a bottleneck in 
interpretation of results. As new bioinformatics tools are designed, more information will be 
derived from data obtained from high throughput sequencing platforms.
NGS Technologies and Metabolomics in Gut Microbiome Research
Connections between microbes and host health were postulated before the advent of high 
throughput sequencing technology [27]. However, prior to technological advancements, 
these studies lacked the ability to take entire community dynamics into consideration. The 
identification and relative quantification of microbial taxa via high-throughput sequencing 
drastically improved the ability to study the gut microbiome. While initially focused on 
compositional studies (who is there?), microbiome researchers became increasingly 
interested in determining functionality (what are they doing?) and identifying modulators 
and mechanistic networks within complex microbial ecosystems (how do microbes 
interact?) (Figure 1).
Today, one standard method for determination of gut microbiome composition is performed 
by isolation of total DNA from samples, PCR amplification of regions within universally 
conserved 16S/18S rRNA genes, followed by high-throughput sequencing of those 
amplicons. This technology has eliminated the need for cloning individual genes, blotting 
for specific RNA, or cultivating individual microbes to identify members of a community. 
High-throughput amplicon sequencing has generated a wealth of data on microbiome 
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composition from different environments and conditions including the gut microbiome of 
~1000 year old preserved human remains, which showed that, similar to modern day 
humans, Firmicutes was the dominant bacterial phylum within the gut at that time [28]. The 
study of the gut microbiome throughout history may give some insight into the differences 
between modern humans and our ancestors, and provide new understanding of diseases that 
have arisen more recently in history. In 2012, the Human Microbiome Consortium (HMC) 
published reference metagenomes of microbes present within healthy humans. Although 
HMC data, obtained predominantly by use of 16S rRNA sequencing and Quantitative 
Insights Into Microbial Ecology (QIIME) [29] analysis, showed that the dominant microbial 
taxa in the human gut include Bacteroidetes, Firmicutes, and Proteobacteria, and that species 
including Bacteroides fragilis, Bacteroides melaninogenicus, Enterococcus faecalis, and E. 
coli are present in the majority of healthy human subjects [30] (Figure 1), other studies have 
suggested that no bacterial species is present within 100% of subjects [31, 32]. It is 
important to note that taxonomic characterization of the microbiota does not always 
translates into function, despite the fact that compositional changes often do result in 
functional changes. In order to effectively understand the impact of the microbiome on the 
host, it is critical to connect compositional to functional studies by combinations of NGS 
technology and functional microbiological assays.
NGS technology has provided the opportunity for studies focusing on complex microbial 
systems to be performed more effectively than ever before. However, biases introduced by 
PCR based sequencing platforms can skew results, over or underestimating bacterial 
abundance [33, 34]. When performing 16S rRNA amplicon sequencing, primer efficiency, 
PCR amplification conditions, sequences platform, bioinformatics pipeline, and protocols 
for DNA extraction and sample handling can all introduce biases to results [32]. The 
Microbiome Quality Control project (MBQC), a consortia of scientists aiming to standardize 
microbiome studies, has shown that difficulty in producing reproducible results in 
microbiome studies are largely a consequence of these internal biases [35].
Whole genome shotgun (WGS) sequencing extends the information provided by 16S/18S 
rDNA amplicon sequencing allowing the identification of DNA viruses and providing 
information about gene content and metabolic pathways [36]. The gut virome is dominated 
by bacteriophages (predominantly bacterial DNA viruses), but includes a diverse population 
of both DNA and RNA encoded eukaryotic viruses [37, 38]. The virome has an important 
role on host health by modulating the bacterial community, as well as by interacting directly 
with host cells [37, 39]. However, virome data is often omitted from microbiome 
compositional studies, as currently most studies are based on 16S/18S rRNA amplicon 
sequencing data. Bacteriophages can modulate composition of the microbiome by killing 
their bacterial hosts during their lytic growth or by altering gene expression during lysogenic 
conversion [40]. Additionally, eukaryotic viruses and bacteriophages in the gut have been 
shown to encode genes involved in DNA replication, amino acid, lipid, and carbohydrate 
metabolism, signal transduction, and transcription regulation [37, 38].
By gaining information about all DNA present, it is possible to infer functionality of 
microbes within the community by comparing identified genes and predicted proteins from 
sequence data to databases including the Kyoto Encyclopedia of Genes and Genomes 
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(KEGG) [41]. In a recent study, WGS in combination with 16S rRNA sequencing showed 
significant differences in diversity and species richness between the gut microbiome 
individuals of different ages and ethnicities. Functional analysis from WGS data showed that 
the microbiota of children and adults differed in the abundance of genes involved in amino 
acid metabolism, lipopolysaccharide (LPS) biosynthesis, RNA degradation, and steroid 
hormone biosynthesis, suggesting differences in the functional potential of the microbiota 
[42]. While a great deal of information can be obtained through WGS, a drawback is that the 
generated functional information represents only potential functions since genes identified 
may or may not be actually expressed within the community under the studied conditions.
As sequencing technology has improved, it has become possible to better study the activity 
of microbes within complex communities. RNA sequencing (RNAseq) permits the analysis 
of gene expression adding valuable expression data to compositional data sets [43], as well 
as providing compositional data for active microbes within the community [44]. 
Metatranscriptome data from the gut microbiome has shown that nearly 50% of genes 
actively expressed are involved in transport and metabolism of carbohydrates, amino acids, 
nucleic acids and lipids, as well as energy production and conversion, indicating that the 
microbiota enhances the metabolic potential of the host [44]. Transcriptome data can be used 
to explore the effects of perturbations and environmental factors on the function of the gut 
microbiome. Furthermore, transcriptome data can identify microbiome functional change 
before a compositional change occurs [45, 46]. For example, bacterial ribosomal proteins are 
generally overexpressed in a healthy microbiome [45] and a decline in ribosomal protein 
expression can occur when microbial growth rates begin to decline, but prior to a change in 
the microbial population. This could serve as a diagnostic tool to detect signs of dysbiosis 
prior to the onset of disease. Finally, transcriptome data can provide information about 
bacteriophage prevalence and activity within the community, which is often overlooked [47].
In addition to using RNAseq to understand microbe-microbe interactions and microbial 
activity within the gut, transcriptome data collected from host cells provide information 
regarding interactions between host and microbiome. Recent studies have shown that the 
microbiota directly alters the transcriptome profiles of its host, with as much as 10% of the 
transcriptome being regulated by the microbiome [48]. However the mechanisms by which 
this transcriptome modulation occurs is largely unknown.
Understanding of the entire pathway from gene sequence to function is completed by 
metabolomics analyses of gut samples. Identification of metabolites produced within the gut 
microbial community provides a detailed picture of functionality and a better understanding 
of physiology. Most microbial metabolic processes like carbohydrate fermentation generate 
byproducts that impact the community as well as the host. One example is the fermentation 
of carbohydrates into short-chain fatty acids [49], which act as signaling molecules to both 
host and other microbes [50, 51]. Traditionally, mass spectrometry (MS) and nuclear 
magnetic resonance (NMR) have been the primary tools used in metabolomics analyses. 
Advancements to those technologies, including Matrix-Assisted Laser Desorption Ionization 
time of flight (MALDI-TOF), Secondary Ion Mass Spectrometry (SIMS), and Fourier 
transform ion cyclotron resonance MS have improved the throughput and accuracy of 
metabolomics studies [52-54].
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Advancements in Culturing Technologies
The information provided by compositional and functional studies of the gut microbiome 
have permitted inference of microbial interactions within complex communities. After 
determining the composition of the gut microbiome, and the microbial genes and pathways 
impacted by health or disease condition, the next logical step is to address the mechanistic 
networks involved in microbiome-host interactions. In order to explore the mechanisms by 
which individual microorganisms modulate the microbiota and host physiology, they must 
be identified, isolated, and studied in pure cultures and microbial consortia. Unfortunately, a 
relatively small percentage of microbes that reside within the gut are cultivable. Although 
recent studies using gnotobiotic mice and anaerobic culturing techniques were able to 
successfully culture ~50% of bacterial species identified by 16S rDNA amplicon 
sequencing, covering nearly 70% known genera and >90% families [55, 56], most of the 
diversity present in the gut microbiome is at the strain level making identification and 
cultivation a difficult task.
Live gnotobiotic animals provide novel methods for cultivation of difficult to grow microbes 
[56], and to study gut microbe-host and microbe-microbe relationships [57]. Colonization of 
gnotobiotic mice with defined gut microbial consortia showed that bile acids were 
significantly reduced in mice colonized with a community containing Bacteroides ovatus, 
while plant-derived quinic acid reached its highest levels when Odoribacter splanchnicus 
was present but E. coli was absent [57], suggesting microbe-specific interactions were 
modulating the host's metabolic potential. Furthermore, humanized gnotobiotic animal 
models have been instrumental in understanding the effects of the human gut microbiota on 
its host. By colonizing germ-free mice with healthy human gut microbiota via fecal 
microbiota transplantation, researchers showed that humanized mouse gut microbiota 
successfully transferred from generation to generation without loss of microbial diversity 
[58] resulting in a method to grow and study human-associated microbes within gnotobiotic 
animal models.
Advances in culturing technology including use of anaerobic conditions and gnotobiotic 
animals have advanced traditional microbiology approaches, as many previously 
uncultivable microbes can now be cultured in lab settings designed to imitate their natural 
growth conditions, allowing the isolation of previously uncharacterized species [59]. A 
device specifically designed to identify uncultivable microbes within complex microbial 
ecosystems is the isolation chip (iChip). iChip consists of a chamber containing multiple 
cells that isolate microorganisms within a mixture while allowing for passage of nutrients 
[60]. While iChip was intended for drug discovery and identification of microbes in 
environmental samples, the technology has the potential for isolation of uncultivable gut 
microbes. A derivative of this technology (I-tip), which uses the same premise as iChip, 
trapping individual microbes within a gel that allows for passage of metabolites and 
nutrients, but at a smaller scale, has already been applied for in situ isolation of microbes 
from invertebrate organisms yielding isolates from 34 novel microbial species across 5 
major phyla [61].
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New culturing technologies and the information provided by NGS have together made high-
throughput culturing possible [59, 62]. Growing individual community members at the same 
time under automated conditions permits a more rapid and thorough study of a community 
as a whole. By utilizing a combination of microfluidics and fluorescence-activated cell 
sorting (FACS) technologies, it has become possible to isolate and culture microbes based 
on the generation or consumption of metabolites in a high-throughput fashion [62] using 
fluorescent reporters for specific molecules to screen diverse microbial populations for 
individuals producing metabolites or enzymes of interest, or screening for mutations in 
known pathways.
Moreover, advancements in culture control technologies have made it possible to simulate 
gastrointestinal (GIT) conditions such as acidity and bile concentration [63]. The simulator 
of human intestinal microbial ecosystem (SHIME) has been used to establish stable, reactor-
grown gut microbial communities. SHIME uses a series of linked reactors each of which 
simulates a different region of the human gastrointestinal tract. When colonized by 
microbes, each region of the simulator has a unique microbial community, similar to the 
living host, including the prevalence of Bacteroides/Prevotella and Lactobacillus in the 
‘colon’ [64]. Similarly, Robogut has been used for in vitro cultivation [65] to produce 
microbial stool substitutes for use in treatment of C. difficile infections [66].
Finally, new microscopy and imaging technologies have a remarkable importance in 
microbiome research [67], permitting direct observation of microbial colonization, location, 
and microbial and host-microbial interactions in the intestine. In a recent study, 
immunofluorescence images of gut cross sections were used to demonstrate how dietary 
changes directly impact host-microbe interactions. Specifically, elimination of microbiota-
accessible carbohydrates from the diet increased the proximity of microbes to the 
epithelium, increasing expression of the inflammatory marker REG3β [68].
Use of in vitro systems to study gut microbial ecology is a useful tool to study the effects of 
perturbations within microbial communities; however, it lacks the ability to factor in host-
specific modulators of the gut microbiota.
In vitro Simulation of the Host-specific Gut Microenvironment
Most microbiota studies have been carried out on animal models; however, this method is 
costly, both from financial and temporal standpoints. A review outlining the study of the 
microbiota in animal models has discussed the importance of animal models in microbiome 
studies [69]. While animal models hold great importance for understanding host-microbe 
interactions, advancements in engineering of biomaterials have recently provided an optional 
approach to study the complex interactions occurring within the gut microbiome. It is now 
possible to construct in vitro systems that simulate intra-organ micro ecosystems, permitting 
high-throughput microbiome studies by engineering microfluidic devices that can be seeded 
with cultured host cells [70]. The system provides a method for studying microbial 
interactions in a highly controlled ‘host’ background. These gut-on-a-chip systems have a 
number of potential uses including nutrition research (Box 2). By having precise control of 
nutrient input, effects of beneficial gut modulators (prebiotics) on microbial content and 
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host cell health could be assayed. Microfluidic devices can also be used to study microbe-
microbe interactions, including microbial behaviors [71]. As an example of microbe-
microbe interactions, chemotaxis/chemical attraction has been shown to be more effectively 
studied using microfluidic devices than traditional capillary-based assays, showing 
chemotactic velocities of over double values obtained utilizing previous methods (as high as 
35% of swimming speed for E. coli) [72].
In another recently developed in vitro system, colonic and intestinal stem cells were 
employed to grow three-dimensional ‘organ-like’ structures within a matrigel overlay 
without utilization of microfluidics technology [73]. Using a microraft array, individual 
colonospheres (spherical three-dimensional structures grown from colonic stem cells) or 
enterospheres (intestinal stem cells) were collected from an array containing individually 
grown structures [74]. The three-dimensional spheres continued to grow, budding and 
forming crypts, simulating the gut in vivo. These microstructures have been primarily used 
to study stem cell differentiation and growth, but this technology provides a valuable 
platform to study gut microbial interactions. Microbial suspensions can be microinjected 
into the pseudo-lumen of colonoid or enteroid structures, which then could be recovered and 
assayed for microbial content, microbial transcriptomics, and host gene expression profiles. 
This technology is still in its infancy, but may provide novel and valuable methods for higher 
throughput microbiome studies than existing models. Moreover, addition of automated 
injection and harvesting mechanisms may provide in the future a platform for high 
throughput microbiome studies.
Advancements in Gut Microbiome Modulation and Host Health
Advancement of microbiome research technology converges at one point: the identification 
and study of microbiome modulators and their impact on host health. As technology and 
research advance, an iterative process is established where well characterized modulators 
can be applied in the discovery of other parameters that impact the gut microbiota. Any 
compound, microbe, or environmental factor that results in a compositional or functional 
modification of the microbiome can be considered a microbiome modulator. Modulators can 
act as short-term modulators or as long-term modulators, and can result in microbiome 
alterations either beneficial or detrimental to host health (Table 1). As such, modulators 
could be used to specifically alter microbiome function or content as a mechanism to prevent 
and treat diseases.
Studies have highlighted diet as the most relevant modulator of the gut microbiome [3, 
75-79], which can function as both a long and short-term modulator and act as either a 
beneficial or detrimental modulator. High fat diets, for example, promote growth of 
Firmicutes and decrease Bacteroidetes, resulting in a microbial composition associated with 
obesity [80]. Consequently, dietary supplementation is one of the most easily performed 
means to beneficially modulate the microbiota [81, 82]; however, the specific activities and 
impact of supplements are unknown due to the complexity of the microbial community. For 
instance, vitamin B12 is a limited resource within the gut, and supplementation promotes 
growth of microorganisms that would otherwise be restricted by its absence but the precise 
mechanisms and pathways involved in B12 metabolism have not yet been elucidated [82].
Arnold et al. Page 8
Trends Microbiol. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Dietary supplementation with prebiotics also functions to positively modulate the gut 
microbiota by promoting growth of beneficial microbes [79, 83]. While humans are unable 
to metabolize specific ingested compounds, the microbes residing within the gut, 
predominantly the distal colon, are rich with metabolic diversity. This vast metabolic 
potential allows for the breakdown of indigestible compounds into components that may be 
utilized by the host or by other microbes [79, 84]. For example, dietary galacto-
oligosaccharides (GOS) promote growth of Bifidobacterium and other beneficial bacteria by 
selective fermentation by gut microbes [85-87]. As the information regarding prebiotic 
modulation of the gut microbiota becomes more readily available, new prebiotic compounds 
will undoubtedly arise with specific modulatory functions.
Likewise, it is accepted that probiotics generally have a short-term beneficial effect on the 
gut microbiota [88, 89], promoting growth of other beneficial microbes, and facilitating host 
immune response. Members of the lactic acid bacteria (LAB) group including several 
species of lactobacilli are commonly regarded as probiotics. One of the most commonly 
studied probiotic Lactobacillus species is L. rhamnosus, specifically Lactobacillus 
rhamnosus GG (LGG). LGG was isolated from a healthy human adult and identified as a 
probiotic bacteria based on its resistance to the conditions of the foregut and its ability to 
adhere to mucosal membranes surrounding gut tissue [90]. L. rhamnosus also has an effect 
on host gene expression and immune response, activating nuclear factor-κB (NF-κB), 
protein kinase C, and phosphoinositide 3-kinase (PI3K) pathways [91, 92]. Probiotics 
including species of Bifidobacterium, Lactobacillus, and Saccharomyces are regularly 
administered as interventions to correct dysbioses caused by disease, chemotherapy or other 
drug treatments [89]. By understanding the molecular mechanisms by which probiotic 
microbes modulate the gut microbiota through a combination of NGS and microbiology 
approaches, it becomes possible to develop tailored microbial interventions to treat or 
prevent specific chronic and acute gastrointestinal diseases.
Novel methods for selective microbiome modulation, including antibiotic treatment [93], 
bacteriophage therapy [94-96], dietary supplementation [87], fecal microbiota 
transplantation [66, 97], and probiotic microbial interventions [88] all provide opportunities 
to specifically control the composition and/or function of the gut microbial community (Box 
3).
Concluding Remarks and Future Directions
There is a wealth of untapped information within the gut microbiome. Information about the 
countless biological processes occurring in this complex microbial community, which are 
not entirely understood, provides valuable insight into microbial impact on host health. The 
data obtained by high-throughput sequencing contains more information than can be 
analyzed effectively using existing bioinformatics platforms and microbiology techniques. 
However, as technology advances, it becomes easier to delineate this data, elucidating 
mechanisms by which microbes impact their host and other members of the gut microbial 
community. Identification and characterization of previously unknown modulation 
mechanisms of the gut microbial community will facilitate the advent of technology for 
microbiome editing to prevent, detect and treat disease (see Outstanding Questions).
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With faster and more cost effective sequencing platforms and data analysis pipelines, the 
idea of using microbiome content as a biomarker for disease is rapidly becoming a 
possibility. Furthermore, advancements in culturing techniques allow for the customization 
of synthetic microbial consortia and permit the study of microbe-microbe interactions within 
complex systems. Therefore, the ability to customize gut microbial consortia will advance 
individualized medicine. By using high-throughput cultivation technology of a previously 
characterized microbial community, the gut microbiota of an individual can be grown and 
used to derive modulators that will specifically repair dysbioses within that individual, 
potentially reducing or curing disease.
Together, these technological advancements make new gut microbiome research initiatives 
possible. As a major modulator of human health, the gut microbiome will continue to attract 
researchers from diverse scientific backgrounds, while advancements in technology from a 
wide range of scientific fields will continue to provide the tools needed to further unlock the 
potential of the gut microbiota as a target for personalized medicine.
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Glossary
16S rRNA
Universally conserved bacterial ribosomal RNA gene. 16S rDNA is regularly the target for 
sequencing microbial metagenomes.
Cultivable
Able to be grown conventionally by traditional microbiology approaches.
Dysbiosis
Compositional or functional shift within host-associated microbial communities that have 
the potential to facilitate growth of pathogens and/or onset chronic diseases.
Denaturing gradient gel electrophoresis (DGGE)
Method that utilizes a poly-acrylamide gel with increasing concentration of denaturing 
chemicals (SDS, urea, etc.) at constant temperature. PCR products run through the gel 
separate based on nucleotide composition, and different sequences appear as different bands 
on the gel
Metabolome
Profile of existing intermediate and end products of metabolic pathways within a system 
under a given set of conditions.
Microbiome
All nucleic acids composing a complex microbial community.
Microbiome modulators
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Any compound, microbe, or environmental factor that results in a compositional or 
functional modification of the microbiome.
Microbiota
Ecological community of commensal, symbiotic and pathogenic microorganisms in a 
particular site, habitat, or geological period
Microfluidics
Multidisciplinary field intersecting engineering, physics, chemistry and biology. 
Microfluidics systems are designed such that low volumes of fluids can be processed to 
achieve high-throughput screening, multiplexing, and/or automation.
Prebiotic
A selectively fermented compound that results in specific changes in the composition and/or 
activity of the gastrointestinal (GI) microbiota thus conferring benefit(s) upon host health.
Probiotics
Live microorganisms which, when administered in adequate amounts, confer a health benefit 
on the host.
Temperature gradient gel electrophoresis (TGGE)
Similar to DGGE but uses variable temperature and a constant detergent concentration.
Terminal-restriction fragment length polymorphism (T-RFLP)
PCR amplification with labeled primers generally targeting the 16S rRNA gene followed by 
restriction digest of products and detection of fluorescent-labeled fragments. Since different 
sequences yield different sized fragments, profiles of microbial communities based on 
sequence dissimilarities can be generated through this procedure.
Metatranscriptome
All RNA molecules, including mRNA, rRNA, tRNA and other non-coding RNA transcribed 
in a population.
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Box 1. Bioinformatics Tools Applied to Gut Microbiome Research
Microbiome bioinformatics seeks to provide computational methods and techniques, 
complementing experimental approaches, to enrich our understanding of complex 
microbial communities, their internal interactions, and their interactions with host and 
environment. Current bioinformatic practice, in many respects encapsulated in the 
software platforms Mothur [98] and QIIME [29], focuses on processing high throughput 
sequencing of variable regions of bacterial 16S ribosomal genes with an emphasis on 
exploratory data analysis and visualization of taxonomic composition. Emerging 
bioinformatics approaches enhance these techniques with improved statistical rigor and 
provide insight into the complex environmental context through complementary 
taxonomic diversity analysis, whole genome shotgun (WGS) and metatranscriptomic 
sequencing.
At its most fundamental level microbiome bioinformatics is founded on the concept of 
operational taxonomic unit (OTU) determination. Although relatively naive hierarchical 
clustering models can be sufficient in some analyses, a much richer probabilistic model 
of clustering provides a much more nuanced analysis that is relatively free of the 
potentially negative ramifications of having to select arbitrary thresholds for parameters 
that are difficult or impossible to estimate given experimental data. Recent developments 
in OTU selection focus on vitiating the effects of essentially arbitrary parameters [99], 
determining what complementary information can be gleaned from the sequencing results 
without OTU selection [100, 101], and deriving the most information from the OTUs that 
are selected. Oligotyping [102, 103] applies information theoretic approaches to subsets 
of reads identified a priori, such as those reads within a particular OTU or categorized 
within a particular phylum, to differentiate biologically relevant distinctions resulting in 
significantly improved taxonomic resolution. Bayesian approaches to OTU selection, 
such as MicrobeDMM [104], are proving successful in a number of studies [104, 105]. 
These approaches not only afford a richer probabilistic model of clustering, but also 
inherently support the inclusion of prior information and additional information sources.
As data sets from diverse experimental sources become available, the possibility of 
exploiting complementary bioinformatics analyses becomes possible. In addition to 
providing robustness to spurious conclusions and enhanced reproducibility, statistically 
rigorous methods provide meaningful metrics to evaluate and compare bioinformatic 
results across diverse analyses required for comprehensive meta-analyses. In order to 
achieve a meaningful synergy of diverse information sources such as taxonomic [106] 
and functional [107, 108] profiling, the results of multiple bioinformatic analyses and 
meta-analyses need to be combined in a principled manner. Preliminary investigations in 
this direction have produced promising results [45, 109, 110], but significant 
development opportunities remain.
Arnold et al. Page 18
Trends Microbiol. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Box 2. Stem Cell Derived Organoids and Microbiome Studies
Medical research and regenerative medicine studies using stem cell technology have 
recently provided insight into organ development in vivo. Individual intestinal stem cells 
have been grown into fully differentiated ‘mini-guts’, providing a platform to study cell 
signaling in gastrointestinal development [111]. The field of stem cell biology has 
advanced significantly in recent years, allowing for the advent of high throughput ‘organ-
on-a-chip’ systems to study development, differentiation and physiology of developing 
organs [112]. Gut-on-a-chip models initially utilized Caco-2 cells (a cell line derived 
from human colorectal adenocarcinoma [113]) grown on extracellular matrix (ECM) 
coated flexible membranes attached to microfluidics channels, subject to peristaltic-like 
movements and fluid flow [112]. This method simulated the gut microenvironment, 
stimulating Caco-2 cells to form three-dimensional villi-like structures [114]. The micro-
devices were predominantly used to study physiology of host cells under various 
treatment conditions, including co-culture with specific microorganisms. Use of this 
three-dimensional microenvironment colonized with gut dwelling microbes [70] 
demonstrated that microbe-induced inflammation within epithelial cells was sufficient to 
compromise the intestinal barrier [115].
Stem cells are capable of initiating morphogenesis generating complex structures in vitro. 
Consequently, use of stem cell-derived organoids colonized with microbial consortia can 
allow for a much more detailed study of microbe-microbe interactions in a highly 
controlled microenvironment providing a high throughput alternative to gnotobiotic live 
animal models. Membrane-free three-dimensional stem cell derived organoids have been 
generated using individual intestinal stem cells or intact crypts harvested from mice [74] 
and human induced pluripotent stem cells [116]. These organoids, which contain various 
differentiated cell types, form a barrier similar to that of intestinal or colonic epithelia 
[74, 116] and have been recently used to show that Salmonella enterica serovar 
Typhimurium can successfully invade the epithelial cell layer [116] and that Clostridium 
difficile can disrupt epithelial barrier function [117]. These studies opened the door for 
the use of stem cell technology to study interactions within the gut microbiota, as well as 
between the microbiota and its host.
Moreover, the genetic background of the stem cell derived organoids can be controlled; 
as stem cells harvested from a living subject can be grown into organoids (Figure I). This 
permits for host-specific microbiota-directed disease interventions to be screened for, and 
tested in a high throughput fashion prior to live animal testing. This may ultimately allow 
for the identification and testing of patient-specific interventions for chronic 
gastrointestinal diseases much more rapidly than has ever been possible in the past.
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Box 3. Selective Modulation of the Gut Microbiota: Microbiome Engineering
Gut dysbioses have been repeatedly linked to human disease; hence the gut microbiota 
has become an increasingly attractive target for disease interventions [2, 118, 119]. By 
using modulators of the gut microbiota, composition and function of the microbial 
community can be selectively altered. Mechanistic studies of gut microbiota modulation 
are scarce [79], however, knowledge from studies of that nature will allow state-of-the-art 
modulators to arise as treatments for chronic and acute human diseases.
Amongst recognized selective modulators of the gut microbiota are bacteriophages, 
probiotics, prebiotics, antibiotics, and engineered synthetic bacterial consortia. 
Bacteriophage-mediated culling of specific members of the microbiota may alter 
microbial composition and free previously occupied niches for novel colonization [95]. 
Conversely, dietary prebiotic supplementation promotes growth of beneficial microbes, 
allowing them to survive and colonize their host better than others within the 
community[63, 87, 120]. Probiotic modulation often combines these two mechanisms, 
both promoting growth of beneficial microbes and selecting against microbes that may be 
detrimental to the host [88, 90]. Similar to probiotics, use of fecal microbiota transplants 
from healthy donors, or cultivated by in vitro gastrointestinal simulators have recently 
arisen as a method to restore gut dysbiosis as well as to treat gastrointestinal disease by 
almost instantaneously modifying microbial composition and the gut microenvironment 
[97, 121].
Combinatory modulation of the gut microbiota is an emerging frontier in gastrointestinal 
medicine. Antibiotic treatments have been shown to enhance the efficacy of microbiota 
transplants, improving the likelihood of colonization by implanted microbes [122]. 
Prebiotic treatments in conjunction with probiotic supplementation allow for more 
effective growth of probiotic microbes and improved function[63].
Finally, microbiome engineering and synthetic biology will demonstrate mechanisms by 
which it may become possible to selectively engineer the composition of the gut 
microbiota. Engineered T7 bacteriophages containing modified tail fibers have already 
been generated with the ability to infect and eradicate specific microbes from a 
population based on tail fiber specificity [96]. This modular construction of synthetic 
bacteriophages allows for very specific targeting of a very broad array of different 
bacteria. Moreover, novel delivery systems permit bacteriophages to be administered as 
food supplements, improving localization and impact of the treatment [123]. Combining 
these technologies may provide a method to selectively eliminate individual detrimental 
members of a microbiota as a way to fight dysbiosis and disease.
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Outstanding Questions
-Can the gut microbiota be used as a reliable biomarker for early detection of chronic 
diseases? Advancements in NGS technology allow for rapid identification of members of 
microbial communities. If dysbiosis within the gut can become a reliable biomarker for 
chronic disease, it may be possible to devise strategies to treat these diseases prior to 
onset.
-What are the impacts of uncultivable microbes within the gut on their community and 
host? Mechanistic studies of microbes are dependent on microbial cultivation. 
Advancements in cultivation technologies will provide information regarding network 
interactions between host, community, and previously uncultivable microbes.
-What role do bacteriophages play in the gut microbiome? As understudied members of 
the gut microbiome, the diversity and role of bacteriophages within the community is 
often overlooked, and in many cases unknown.
-How do various members of the gut microbiota modulate host gene expression? Can this 
information be useful in disease prevention? Gut microbes influence host gene expression 
directly and indirectly. While not all microbial mechanisms to modulate host gene 
expression are known, more and more information regarding microbiota-modulated host 
gene expression is emerging as technology advances. Knowledge of how host gene 
expression is controlled by microbes may allow for the engineering of microbes to 
selectively control expression of target genes.
-Will the use of patient stem cell derived organoids and microbiota become common 
practice in the development of personalized treatments for chronic gastrointestinal 
diseases? By using freshly harvested intestinal stem cells, organoids can be grown 
containing the precise genetic background of the patient. These organoids can 
subsequently be colonized by the microbiota from the patient, and subjected to treatments 
in a high throughput fashion in order to test efficacy of specific interventions.
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Trends Box
-Compositional and functional analyses of the gut microbiome by next-generation 
sequencing methods have completely transformed research approaches to determine 
microbial species and their role in human health and disease.
-New culturing technologies facilitate mechanistic studies of difficult to culture gut 
microbes. A number of previously uncultivable microbes are now cultivable as a result of 
these advancements, providing insight into community dynamics and network 
interactions.
-Stem cell technologies and tissue engineering allow for construction of organoids 
capable of facilitating cost effective, high-throughput microbiome studies.
-Modulation of the gut microbiota is emerging as an effective method to delineate 
composition and function of microbial communities providing new methods to prevent 
and treat disease.
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Figure I. A Microbiome-Organoid Array to Study the Impact of Gut Microbiome Modulators on 
Individual Hosts
A) Host-derived organoid arrays could derive personalized treatments and diagnostics based 
on genetic background (GB) and gut microbiome composition. Individual organoids can 
subsequently be harvested and screened for microbial composition, microbial transcriptome, 
and host gene expression with the aim of identifying an effective treatment for the 
individual. B) Mouse small intestine stem cell-derived enteroid from days 4 to 7. 
Photographs show progression of the organoid from a sphere to mature colonoids presenting 
crypt-like structures.
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Figure 1. 
Timeline of major advancements on gut microbiota studies. Research centered around low-
cost high-throughput next generation sequencing began to emerge in the past 10 years. 
These advancements have provided the opportunity to study complex communities and their 
impact on host health, and culmination of these technologies is driving the field toward a 
future of personalized medicine. Taxonomic determination of microbes dwelling in the gut 
by 16S rRNA sequencing was first performed in the late 1990s. Dysbiosis and its impact on 
human disease was first discussed in early 2000s, and identified in colorectal cancer [133] 
among other diseases including Crohn's disease. Since 2010, rapid advances in 
bioinformatics including Quantitave Insights into Microbial Ecology (QIIME) for analysis 
of metagenome have been used to identify core members of the gut microbiota of healthy 
humans [134] as well as the impact of perturbations on gut microbial communities [135]. 
Finally, biology and engineering sciences converged in the design of ‘Gut on a Chip’ devices 
to simulate gastrointestinal environments [70].
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Table 1
Examples of Modulators of the Gut Microbiota
Modulator type Example Impact on host Duration/rate Effects on the microbiota
Prebiotics β, 1-4 Galacto-
oligosaccharide 
(GOS)
Beneficial Short-term/intermediate Promotes growth of 
Bifidobacterium and Lactobacillus 
[124]
Inhibits growth of Clostridium 
[125]
Increases recovery rate of 
microbiota post-antibiotic treatment 
[126]
Probiotics L. rhamnosus GG Beneficial Short-term/intermediate Inhibits growth/colonization of 
pathogenic microbes [90, 127]
Promotes growth of 
Bifidiobacterium sp. [128]. 
Modulates host gene expression 
[90]
Bacteriophages 933W coliphage Detrimental Short-term/rapid Modify and/or eradicate 
populations of commensal E. coli 
[129].
Transmits endotoxin genes to 
bacteria within community [130].
Antibiotics/drugs Chemotherapy Beneficial or detrimental Short-term/rapid Culling of microbes to free niche 
space [122]
Host immune response Toll-like receptor 
mediated gene 
expression
Generally beneficial Long-term/rapid Inhibits colonization of certain 
microbes. Eliminates invading 
pathogens from the population. [46]
Diet High fat vs. low fat 
diets
Beneficial or detrimental Long-term/slow Vitamin supplements impact 
transcription and microbial content 
[82, 131]
High fat diets promote ‘unhealthy’ 
microbiota [80]
Transplantation Fecal Transplant Mostly beneficial Long-term/immediate Transplantation of healthy 
microbiota can eliminate 
Clostridium difficile infection [97]
Pathogenic bacteria Salmonella sp. Detrimental Short-term/intermediate Outcompetes other microbes within 
the microbial community, reducing 
community diversity [132].
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